The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO MAP 2022 | Patient-derived xenograft models for preclinical oncology research
Robert Hynds, PhD, UCL, London, UK, discusses patient-derived xenograft models for preclinical oncology research. Whilst the majority of preclinical research relies on cancer cell lines or genetically engineered mouse models, patient derived xenograft models hold the advantage of being more representative of human tumors and are thus more reliable. https://www.biorxiv.org/content/10.1101/2023.01.06.521078v1.full. This interview took place at the Molecular Analysis for Precision oncology (MAP) Congress 2022 in Amsterdam, Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
